Company Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins.
Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC.
The company has collaborations with Pfizer Inc., Genentech, Inc., F.
Hoffman-La Roche Ltd., and Bayer AG.
Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.
| Country | United States |
| IPO Date | Sep 27, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 445 |
| CEO | Dr. John G. Houston Ph.D. |
Contact Details
Address: 5 Science Park New Haven, Connecticut United States | |
| Website | https://www.arvinas.com |
Stock Details
| Ticker Symbol | ARVN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001655759 |
| CUSIP Number | 04335A105 |
| ISIN Number | US04335A1051 |
| Employer ID | 47-2566120 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. John G. Houston Ph.D. | Chairperson, Chief Executive Officer & President |
| Andrew R. Saik | Chief Financial Officer & Treasurer |
| Angela M. Cacace Ph.D. | Chief Scientific Officer |
| Dr. Ian Taylor Ph.D. | President of Research & Development and Chairman of Scientific Advisory Board |
| Dr. Randy Teel Ph.D. | Chief Business Officer |
| Jared M. Freedberg J.D. | General Counsel & Corporate Secretary |
| John P. Northcott | Chief Commercial Officer |
| Lisa Sinclair | Senior Vice President of Corporate Operations |
| Paul McInulty | Senior Vice President of Regulatory Affairs |
| Steve Weiss | Senior Vice President & Chief Human Resources Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 10, 2024 | 8-K | Current Report |
| Nov 19, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 12, 2024 | 4 | Filing |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Oct 30, 2024 | 10-Q | Quarterly Report |
| Oct 30, 2024 | 8-K | Current Report |
| Oct 22, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Sep 10, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |